TRxADE HEALTH Statistics
Total Valuation
TRxADE HEALTH has a market cap or net worth of $8.35 million. The enterprise value is $13.44 million.
| Market Cap | 8.35M |
| Enterprise Value | 13.44M |
Important Dates
The next estimated earnings date is Monday, May 13, 2024, after market close.
| Earnings Date | May 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
TRxADE HEALTH has 1.21 million shares outstanding. The number of shares has increased by 328.34% in one year.
| Shares Outstanding | 1.21M |
| Shares Change (YoY) | +328.34% |
| Shares Change (QoQ) | +246.92% |
| Owned by Insiders (%) | 28.08% |
| Owned by Institutions (%) | 5.66% |
| Float | 452,083 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.92 |
| Forward PS | 0.90 |
| PB Ratio | 0.72 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.48 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.61, with a Debt / Equity ratio of 0.56.
| Current Ratio | 0.61 |
| Quick Ratio | 0.26 |
| Debt / Equity | 0.56 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -9.29 |
Financial Efficiency
Return on equity (ROE) is -243.20% and return on invested capital (ROIC) is -19.31%.
| Return on Equity (ROE) | -243.20% |
| Return on Assets (ROA) | -85.70% |
| Return on Capital (ROIC) | -19.31% |
| Revenue Per Employee | $275,327 |
| Profits Per Employee | -$215,246 |
| Employee Count | 33 |
| Asset Turnover | 1.10 |
| Inventory Turnover | 1.70 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +41.82% in the last 52 weeks. The beta is 1.93, so TRxADE HEALTH's price volatility has been higher than the market average.
| Beta (1Y) | 1.93 |
| 52-Week Price Change | +41.82% |
| 50-Day Moving Average | 12.13 |
| 200-Day Moving Average | 8.21 |
| Relative Strength Index (RSI) | 37.34 |
| Average Volume (30 Days) | 435,301 |
Short Selling Information
The latest short interest is 34,026, so 2.82% of the outstanding shares have been sold short.
| Short Interest | 34,026 |
| Short Previous Month | 55,975 |
| Short % of Shares Out | 2.82% |
| Short % of Float | 7.53% |
| Short Ratio (days to cover) | 0.06 |
Income Statement
In the last 12 months, TRxADE HEALTH had revenue of $9.09 million and -$7.10 million in losses. Loss per share was -$6.94.
| Revenue | 9.09M |
| Gross Profit | 6.45M |
| Operating Income | -3.48M |
| Pretax Income | -7.10M |
| Net Income | -7.10M |
| EBITDA | -6.06M |
| EBIT | -6.41M |
| Loss Per Share | -$6.94 |
Balance Sheet
The company has $1.36 million in cash and $6.48 million in debt, giving a net cash position of -$5.12 million or -$4.25 per share.
| Cash & Cash Equivalents | 1.36M |
| Total Debt | 6.48M |
| Net Cash | -5.12M |
| Net Cash Per Share | -$4.25 |
| Equity / Book Value | 11.56M |
| Book Value Per Share | 9.59 |
| Working Capital | -3.54M |
Cash Flow
In the last 12 months, operating cash flow was $23,973 and capital expenditures -$114,943, giving a free cash flow of -$90,970.
| Operating Cash Flow | 23,973 |
| Capital Expenditures | -114,943 |
| Free Cash Flow | -90,970 |
| FCF Per Share | -$0.12 |
Margins
Gross margin is 70.98%, with operating and profit margins of -38.34% and -78.18%.
| Gross Margin | 70.98% |
| Operating Margin | -38.34% |
| Pretax Margin | -78.18% |
| Profit Margin | -78.18% |
| EBITDA Margin | -66.66% |
| EBIT Margin | -70.58% |
| FCF Margin | -1.00% |
Dividends & Yields
TRxADE HEALTH does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -328.34% |
| Shareholder Yield | -328.34% |
| Earnings Yield | -85.43% |
| FCF Yield | -1.09% |
Analyst Forecast
The average price target for TRxADE HEALTH is $18.75, which is 170.56% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $18.75 |
| Price Target Difference | 170.56% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on June 22, 2023. It was a reverse split with a ratio of 1:15.
| Last Split Date | Jun 22, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:15 |
Scores
TRxADE HEALTH has an Altman Z-Score of -1.65 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.65 |
| Piotroski F-Score | 4 |